Journal
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 6
Volume 6, Issue -, Pages 95-119Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev.pathol.3.121806.154244
Keywords
genetically engineered mice; gene targeting; oncogene; tumor-suppressor gene; cancer-gene discovery; oncogenomics
Categories
Funding
- NATIONAL CANCER INSTITUTE [R01CA103924] Funding Source: NIH RePORTER
- NCI NIH HHS [R01 CA103924] Funding Source: Medline
Ask authors/readers for more resources
Genetically engineered mouse models have significantly contributed to our understanding of cancer biology. They have proven to be useful in validating gene functions, identifying novel cancer genes and tumor biomarkers, gaining insight into the molecular and cellular mechanisms underlying tumor initiation and multistage processes of tumorigenesis, and providing better clinical models in which to test novel therapeutic strategies. However, mice still have significant limitations in modeling human cancer, including species-specific differences and inaccurate recapitulation of de novo human tumor development. Future challenges in mouse modeling include the generation of clinically relevant mouse models that recapitulate the molecular, cellular, and genomic events of human cancers and clinical response as well as the development of technologies that allow for efficient in vivo imaging and high-throughput screening in mice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available